Navigation Links
Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
Date:11/4/2008

BETHESDA, Md., Nov. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data from a preclinical study(1) showing cytotoxic activity of anti-EpCAM antibody adecatumumab (MT201) against KRAS-mutated human colon cancer cells on November 1, 2008 at the 23rd Annual meeting of the International Society for Biological Therapy of Cancer (iSBTc) , taking place October 31-November 2, 2008 in San Diego, California.

The new preclinical data indicated that human colon cancer cells are efficiently eliminated in tested cell lines by adecatumumab, mediated by antibody-dependent cellular cytotoxicity (ADCC), irrespective of their KRAS mutation status. Recent studies suggest that anti-EGFR antibodies cetuximab (Erbitux(R); ImClone, BMS, Merck KGaA) and panitumumab (Vectibix(R); Amgen) are beneficial for patients with KRAS wild-type tumors, however, show limited or no efficacy in the treatment of colon cancer patients with a mutated KRAS oncogene in their cancer cells. These findings recently led to the approval of cetuximab for first-line therapy in patients with KRAS wild-type tumors. As a consequence, there is a high need for the development of treatment strategies covering those patients who are not able to benefit from this important new treatment option as their tumors carry the KRAS mutated gene. This mutation is found in approximately 35 to 40 percent of patients with this disease.

"Given that more than 95 percent of colon cancer patients strongly express EpCAM on their tumors, and that 35 to 40 percent of patients who have a KRAS mutant tumor may not benefit from treatment with anti-EGFR antibodies, adecatumumab could be investigated as a potential alternative for the treatment of KRAS mutant colon cancer tumors," commented Patrick Baeuerle, senior vice president and chief scientific officer for Micromet.
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 1, 2014 The global high ... marked by the ,Threat of Obsolescence, wherein technologies as ... rapidly. Pharmaceutical and biotechnology companies as well as academic ... content screening as a powerful research tool in drug ... fastest-growing segment in the high content screening market. In ...
(Date:10/1/2014)... 1, 2014   Plexus Information Systems, Inc. ... Information Management Systems (AIMS), announced a partnership with ... wholly owned subsidiary of Quality Systems, Inc. and ... connectivity solutions.  Logo - ... This partnership extends the NextGen Healthcare ...
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... provider for the medical industries, announced today the expansion of its ... New York City . genae Americas was incorporated in 2011. ... centered in one of the highest concentrations of medical innovation and ... , President at genae Americas. "The expansion of genae from ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3genae Opens Offices in New York City 2
... SILVER SPRING, Md., June 8, 2011 The Food and ... containing 80 mg of simvastatin — the highest approved dose ... of the risk of muscle injury. (Logo:   ... only be used by patients who have been taking it ...
... Merz Pharmaceuticals today announced that new data on ... from accessory (complexing) proteins, will be presented at ... of Parkinson,s Disease and Movement Disorders in Toronto, ... XEOMIN were safe and effective in the treatment ...
Cached Medicine Technology:FDA CONSUMER HEALTH INFORMATION - Limit Use of 80 mg Simvastatin 2New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinson's Disease And Movement Disorders (MDS) 2New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinson's Disease And Movement Disorders (MDS) 3
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... roses -- literally -- may face an increased risk of dying ... study of over 3,000 older Americans, researchers found those who were ... more than three times as likely to die in the next ... In fact, anosmia -- the inability to distinguish odors -- was ...
(Date:10/1/2014)... University of Adelaide have developed a model that could ... outcome from treatment - from their very first psychotic ... of factors, including clinical symptoms, cognitive abilities, MRI scans ... blood. , Speaking in the lead up to World ... Psychiatry , Professor Bernhard Baune , says ...
(Date:10/1/2014)... the brain of a rat and a robot could ... QUT leading robotics researcher. , Dr Michael Milford ... study uses new computer algorithms to enable robots to ... "This is a very Frankenstein type of project," Dr ... thing together because we,re taking the eyes of a ...
(Date:10/1/2014)... people to keep their "eyes on the prize" may ... walking, staying focused on a specific target ahead can ... people walk there faster, psychology researchers have found. Their ... around the environment naturally, offers a new strategy to ... interested in exercise if physical activity seems daunting, which ...
(Date:10/1/2014)... October 01, 2014 Bedros Keuilian is ... Boot Camp fitness boot camps, he’s also considered the ... , with sold out business summits, a line of ... consultant to a recent Spike TV reality show to ... now is the time for personal trainers and fitness ...
Breaking Medicine News(10 mins):Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Predicting the future course of psychotic illness 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3
... the #1 co-ed,fitness club chain in the world, has ... has clubs operating in 46 states, Canada and Australia,serving ... other well-known fitness chains have recently scaled back their,expansion ... grow at,an impressive rate. In fact, in the past ...
... the eye region is also useful when trying to spot fatigue ... or less tired? Focus on the area around your eyes, a ... your age and level of fatigue. , When asked to ... looked at the eye region almost half the time, researchers ...
... profound impact on this country,s psyche. Eight years after ... events affected us. A number of studies have shown ... the terrorist attacks experienced heightened levels of stress and ... Research has also indicated that elevated levels of stress ...
... PARK, N.J. and NEW YORK, Feb. 2 HLTH Corporation ... subsidiary, WebMD Health Corp. (Nasdaq: WBMD ), today ... the three months ended December 31, 2008 at approximately 4:00 ... will host a conference call at 4:45 pm (ET) on ...
... SCOLR Pharma, Inc. (NYSE Alternext US: DDD) today announced ... Ph.D., M.B.A., to serve as president and chief executive officer. ... SCOLR Pharma board of directors since August 2007.Michael N. Taglich, ... very pleased that Dr. Morra has agreed to become SCOLR ...
... (TFAH) strongly supports President Obama,s call for a "complete ... outbreak of Salmonella tied to peanut butter ... Salmonella outbreaks in 2008 highlight the need ... released a comprehensive report, Fixing Food Safety: Protecting ...
Cached Medicine News:Health News:Anytime Fitness Opens 1,000th Club 2Health News:Anytime Fitness Opens 1,000th Club 3Health News:When Gauging Age, the Eyes Have It 2Health News:Driving under the influence (of stress): Regional effects of 9/11 attacks on driving 2Health News:HLTH and WebMD Announce Fourth Quarter Earnings Release Date and Conference Call 2Health News:SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO 2Health News:SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO 3Health News:Trust for America's Health Applauds President Obama's Call for a Complete Review of the U.S. Food Safety System 2Health News:Trust for America's Health Applauds President Obama's Call for a Complete Review of the U.S. Food Safety System 3
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
Medicine Products: